SAB Biotherapeutics raises ~$7.9M in private placement of common stock and warrants

SAB Biotherapeutics, Inc.

Gross proceeds ~$7.9M from sale of ~7.36M shares and warrants at $1.08 per unit.
Warrants exercisable after 6 months at $1.08/share, expire in 5 years.
Proceeds to advance C. diff and type 1 diabetes pipeline and for working capital.
Existing investors including T. Denny Sanford and new institutional investors participated.
Brookline Capital Markets acted as exclusive placement agent.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SAB Biotherapeutics, Inc. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $8.0 million (effective 2022-12-06).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional and accredited investors
Value: approximately $8.0 million
Effective: 2022-12-06

Exact text from the filing

On December 6, 2022, SAB Biotherapeutics, Inc. (the “Company” or “SAB”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors

View on SEC.gov

Browse all material agreements →

SAB Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-026346

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.